NCT00070551View on ClinicalTrials.gov

GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

February 28, 2009

Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid Leukemia
Interventions
BIOLOGICAL

GTI-2040

Given IV

DRUG

cytarabine

Given IV

OTHER

pharmacological study

Optional correlative studies

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00070551 - GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter